Taihe Biotech

Taihe Biopharmaceutical (Beijing) Co., Ltd., commonly known as Taihe Biotech, is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery and development of innovative small molecule drugs. Founded in 2015, the company focuses on addressing significant unmet medical needs in oncology and autoimmune diseases through the development of highly selective inhibitors. Its lead candidate, TAE1910, is a selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for rheumatoid arthritis, atopic dermatitis, and alopecia areata. The company's pipeline also includes TAE1612, a dual PI3K delta/gamma inhibitor being evaluated for hematologic malignancies. Taihe Biotech is supported by prominent investors such as IDG Capital and Northern Light Venture Capital and aims to provide differentiated therapeutic options with improved safety profiles. The company leverages its internal drug discovery platform to advance a portfolio of next-generation small molecule candidates toward global markets.